MorphoSys AG will receive a milestone payment from Novartis in connection with the initiation of a Phase 1 clinical trial using a HuCAL-derived, fully human antibody in the therapeutic area of musculoskeletal diseases. This is the second HuCAL-derived antibody to achieve this stage during the course of 2010, following a clinical milestone hit as part of MorphoSys’ alliance with Centocor in June.
“Therapeutic antibodies based on our technologies will be our main value driver in the years ahead and we expect our pipeline to continue to expand and mature. At the end of 2010, we expect MorphoSys to be participating in almost 80 unique product opportunities,” commented Dr Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
MorphoSys projects that in 2010 between four and six partnered programmes could enter clinical trials. With the recently announced in-licensing of an Fc-engineered antibody against CD19 from Xencor Inc, MorphoSys now expects up to 15 proprietary and partnered antibody programmes to be in clinical trials including at least four programmes in Phase 2 clinical trials by year end.
- RSS Feed
